RARE - Wells Fargo starts Ultragenyx coverage with overweight rating
2023-12-08 17:07:24 ET
More on Ultragenyx Pharmaceutical
- Ultragenyx: Speculative Innovation Amidst High Expenditures Merits Caution (Rating Downgrade)
- Ultragenyx Pharmaceutical, Inc. (RARE) Q3 2023 Earnings Call Transcript
- Ultragenyx Pharmaceutical Inc. 2023 Q3 - Results - Earnings Call Presentation
- Ultragenyx Pharmaceutical GAAP EPS of -$2.23 misses by $0.12, revenue of $98.1M misses by $4.78M
- Ultragenyx Pharmaceutical prices $300 million securities offering
For further details see:
Wells Fargo starts Ultragenyx coverage with overweight rating